Clinical trials: Thyroid Disorders
Thyroid Neoplasms
Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer
This is a Phase 2 study being conducted at multiple centers in the United States. Patients having thyroid cancer that has spread to other parts of the body (i.e., metastatic) are eligible to participate.
- Trial name
- NCT00094055
- Testing
- AG013736
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- Pfizer
Solid Tumor
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
This is a first in human (FIH) 2-part study using ACTM-838 in patients with advanced solid tumors resistant to standard of care treatment. Part 1a will evaluate dose escalation and Part 1b will evaluate dose expansion.
- Trial name
- NCT06336148
- Testing
- ACTM-838
- Where
- 5 sites in United States, Australia
- Volunteers
- 10 people
- Sponsor
- Actym Therapeutics, Inc.
Differentiated Thyroid Cancer
A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.
Patients diagnosed with thyroid cancer are commonly treated with surgery to remove their thyroid gland followed by radioiodine ablation to destroy any remaining parts of the thyroid gland that may have been missed during surgery.
- Trial name
- NCT00295763
- Testing
- Thyrogen (thyrotropin alfa for injection)
- Where
- 9 sites in United States, Canada and 3 more
- Volunteers
- 61 people
- Sponsor
- Genzyme, a Sanofi Company
Thyroid Neoplasms
A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer
The purpose of this study is to evaluate the safety of lenvatinib in participants with recurrent, metastatic radio-iodine refractory differentiated thyroid cancer (DTC).
- Trial name
- NCT03573960
- Testing
- Lenvatinib
- Where
- 11 sites in India
- Volunteers
- 50 people
- Sponsor
- Eisai Pharmaceuticals India Pvt. Ltd
Solid Tumors, Advanced Cancer
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
To assess: efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion…
- Conditions
- Solid Tumors, Advanced Cancer, Renal Cancer, Gastric Cancer
- Trial name
- SPARTA (NCT03175224)
- Testing
- APL-101 Oral Capsules
- Where
- 35 sites in United States, Australia and 9 more
- Volunteers
- 497 people
- Sponsor
- Apollomics Inc.
Medullary Thyroid Cancer
A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer
The objective of this study is to evaluate the efficacy and safety of oral cabozantinib at a 60 mg dose compared with a 140 mg dose in subjects with progressive, metastatic MTC.
- Trial name
- EXAMINER (NCT01896479)
- Testing
- Cabozantinib (XL184) 140 mg, Cabozantinib (XL184) 60 mg
- Where
- 49 sites in Australia, Canada and 12 more
- Volunteers
- 247 people
- Sponsor
- Exelixis
Thyroid-Associated Ophthalmopathy
Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment
The main purpose of this study is to evaluate the efficacy and safety of 3 doses of Somatuline Autogel 60mg to control the muscle infiltration and edema, eyelid retraction and extraocular muscular contraction in patients with…
- Trial name
- NCT00288522
- Testing
- Lanreotide (Autogel formulation). Duration of treatment - 3 injections, 1 every 28 days
- Where
- Spain
- Volunteers
- 5 people
- Sponsor
- Ipsen
Medullary Thyroid Cancer
A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).
A study to evaluate the efficacy and safety of pralsetinib compared with SOC treatment (cabozantinib or vandetanib) for participants with RET (rearranged during transfection)-mutant MTC who have not previously received a SOC…
- Trial name
- AcceleRET-MTC (NCT04760288)
- Testing
- Pralsetinib, Cabozantinib, Vandetanib
- Where
- Spain
- Sponsor
- Hoffmann-La Roche
Thyroid Neoplasms
Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
Trial of sorafenib versus placebo in the treatment of locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine
- Trial name
- NCT00984282
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 81 sites in United States, Austria and 16 more
- Volunteers
- 417 people
- Sponsor
- Bayer
Graves Disease
NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease
The purpose of this study is to evaluate how well MER511 is tolerated and what side effects may occur in adults who have Graves' disease.
- Trial name
- NCT07305818
- Testing
- MER511 (IV), MER511 (SC), MER511 (SC) for MAD
- Where
- 17 sites in United States, Spain
- Volunteers
- 100 people
- Sponsor
- Merida Biosciences
Graves' Disease
Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease
This study is being conducted to look at the effect YB-101 has on thyroid function. This study will also evaluate how safe and well tolerated YB-101 is and how it is distributed through the body.
- Trial name
- NCT07682896
- Testing
- Experimental: YB-101
- Where
- 32 sites in United States, Australia
- Volunteers
- 232 people
- Sponsor
- Yarrow Bioscience, Inc.
Hormone Imbalance, Thyroid Hormone Imbalance
A Clinical Trial to Evaluate the Effects of a Supplement on Symptoms Associated With Hormone Imbalance
This study evaluates the effects of the Love Wellness Hello Burn, Balance supplement on symptoms associated with hormone imbalance, as measured by energy levels and healthy eating choices and habits.
- Conditions
- Hormone Imbalance, Thyroid Hormone Imbalance, Low Energy, Metabolic Symptoms
- Trial name
- NCT07765381
- Testing
- Hello Burn, Balance Supplement
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Love Wellness
Solid Tumors
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations
This is a Phase 1 study of JSI-1187 as monotherapy and in combination with dabrafenib for the treatment of advanced solid tumors with MAPK pathway mutations, including mutations that cause MAPK pathway hyperactivation.
- Trial name
- NCT04418167
- Testing
- JSI-1187, Dabrafenib
- Where
- 7 sites in United States
- Volunteers
- 71 people
- Sponsor
- JS InnoPharm, LLC
Thyroid Eye Disease
A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Inactive Thyroid Eye Disease
This is a multicenter, randomized, double-masked, placebo-controlled Phase 3 study to evaluate the efficacy, safety, immunogenicity, and population pharmacokinetic (PopPK) characteristics of KHN939 in Chinese patients with…
- Trial name
- Halo-2 (NCT07720648)
- Testing
- KHN939
- Where
- China
- Volunteers
- 117 people
- Sponsor
- Beijing Kanghong Biological Medicine Co., Ltd.
Differentiated Thyroid Carcinoma
Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer
ST-1898, a multi-targeted tyrosine kinase inhibitor, has demonstrated strong inhibitory activity for VEGFR2, c-MET, AXL, PDGFRA, RET, KIT, etc.
- Trial name
- NCT06359847
- Testing
- ST-1898 tablets
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Scitech-Mq Pharmaceuticals Limited
Hypothyroidism
Study of Dose Adjustment From Levothyroxine to a New Levothyroxine Sodium Test Formulation
The purpose of this study is to investigate the effect of switching participants taking levothyroxine to a new sodium formulation.
- Trial name
- NCT01916304
- Testing
- Levothyroxine sodium new formulation
- Where
- Belgium
- Volunteers
- 101 people
- Sponsor
- Takeda
Nonalcoholic Steatohepatitis (NASH)
Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults With NASH
This is a phase 2, randomized, double-blind, placebo controlled study in adults with biopsy confirmed NASH. The study is aimed at evaluating efficacy and tolerability of ASC41 in adults with NASH.
- Trial name
- NCT05118360
- Testing
- ASC41 2 mg, ASC41 4 mg
- Sponsor
- Gannex Pharma Co., Ltd.
Autonomous Hyperfunctioning Thyroid Nodules
High Intensity Focused Ultrasound Device in Patients With Autonomous Hyperfunctioning Thyroid Nodules
The purpose of this study is to assess the efficacy and safety of High Intensity Focalized Ultrasound (HIFU) in the treatment for toxic Thyroids nodules
- Trial name
- NCT02169687
- Testing
- HIFU
- Where
- France
- Volunteers
- 2 people
- Sponsor
- Theraclion
Graves Disease
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.
The main purpose of this study is to look at how efgartigimod affects thyroid function in adults with Graves' Disease (GD). The study will also check whether efgartigimod is safe and well tolerated.
- Trial name
- VitaliThy (NCT07596849)
- Testing
- efgartigimod PH20 SC
- Where
- 51 sites in Belgium, Bulgaria and 12 more
- Volunteers
- 230 people
- Sponsor
- argenx
Hypothyroidism
Bioequivalence of Two Levothyroxine Tablet Formulations in Healthy Indian Volunteers
GSK markets a drug called levothyroxine or T4 that is used to treat patients with hypothyroidism. Till date, the active drug substance or active pharmaceutical ingredient (API) for levothyroxine tablets marketed in India has been…
- Trial name
- NCT01536678
- Testing
- Levothyroxine
- Where
- India
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline